Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-06-07
2011-06-07
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C536S024100, C435S006120, C435S325000, C435S375000, C514S04400A
Reexamination Certificate
active
07956177
ABSTRACT:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.
REFERENCES:
patent: 5858987 (1999-01-01), Beer-Romero et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2006/0275903 (2006-12-01), McSwiggen et al.
patent: 2007/0004664 (2007-01-01), McSwiggen et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: WO 96/34950 (1996-11-01), None
patent: 03/008573 (2003-01-01), None
patent: WO 03/008573 (2003-01-01), None
patent: 2004/065601 (2004-08-01), None
patent: WO 2004/065601 (2004-08-01), None
patent: WO 2008/116860 (2008-10-01), None
Hengstermann et al. Growth supression induced by downregulation of E6-AP expression in human papillomavirus—positive cancer cell lines depends on p53. J. of Virology 2005, vol. 79: 9296-9300.
PCT International Search Report and Written Opinion, PCT/EP2008/053475, Jan. 19, 2009, 19 Pages.
PCT International Search Report and Written Opinion, PCT/US2007/007241, Apr. 7, 2007, 14 Pages.
Examination Report for European Patent Application No. 08718165.7, Apr. 28, 2010, 4 Pages.
Gewin, L., et al., “Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex” Genes & Development, Sep. 15, 2004, pp. 2269-2282, vol. 18, No. 18.
Patzel, V., et al., “In silico selection of active siRNA” Drug Discovery Today, Elsevier, Jan. 31, 2007, pp. 139-148, vol. 12, No. 3-4.
Shirakura, M., et al., “E6AP ubiquitin ligase mediates ubiquitylation and degradation of hepatitis C virus core protein.” Journal of Virology, Feb. 2007, pp. 1174-1185, vol. 81, No. 3.
Agrawal, S., et al., “Antisense oligonucleotides: towards clinical trials.” Trends in Biotechnology. Oct. 1996, vol. 14, pp. 376-387.
Bass, B., “The short answer,” Nature, May 24, 2001, pp. 428-429, vol. 411.
Elbashir, S., et al., “Analysis of gene function in somatic mammalian cells using small interfering RNAs,” Methods, 2002, pp. 199-213, vol. 26.
Elbashir, S., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture,” Nature, May 24, 2001, p. 494-498, vol. 411.
Elbashir, S., et al., “Functional Anatomy of siRNAs for Mediating Efficient RNAi inDrosophila melanogasterEmbryo Lysate”, The EMBO Journal, 2001, pp. 6877-6888, vol. 20, No. 23.
Elbashir, S., et al., “RNA Interference is Mediated by 21-and 22 Nucleotide RNAs,” Genes & Development, 2001, pp. 188-200, vol. 15.
Fire, A., “RNA-triggered Gene Silencing,” Trends in Genetics, Sep. 1999, pp. 358-363, vol. 15, No. 9.
Fire, A., et al., “Potent and Specific Genetic Interference By Double Stranded RNA inCaenorhabditis elegans,” Nature, Feb. 19, 1998, pp. 806-811, vol. 391.
Tuschl, T., “Functional genomics: RNA sets the standard,” Nature, Jan. 16, 2003, vol. 421, No. 6920, pp. 220-221.
Tuschl T., “RNA Interference and Small Interfering RNAs” Chembiochem, 2001, pp. 239-245, vol. 2.
Tuschl, T., et al., “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions, 2002, pp. 158-167, vol. 2, No. 3.
Tuschl, T., “Mammalian RNA Interference,” RNAi, A Guide to Gene Silencing, Chapter 13, G.J. Hannon (ed,), 2003, pp. 265-295.
Tuschl, T., et al., “Targeted mRNA Degradation By Double-Stranded RNA In Vitro,” Genes & Development, 1999, pp. 3191-3197, vol. 13.
Tuschl, T., “Expanding small RNA interference,” Nature Biotechnology, May 2002, pp. 446-448, vol. 20.
Vickers, T., et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” The Journal of Biological Chemistry, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9.
Liu Xuefeng et al. “The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillmavirus E6 oncoprotein” Journal of Biological Chemistry, vol. 280, No. 11, Mar. 2005, pp. 10807-10816, XP002462387 ISSN: 0021-9258.
Soutschek Juergen et al. “Therapeutic silencing of an endogenous gene by systemic administration of modified siRNA's” Nature, vol. 432, No. 7014, Nov. 11, 2004, pp. 173-178, XP002333747, ISSN: 0028-0836.
Kelley Melissa L. et al. “The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase” Journal of Virology, vol. 79, No. 6, Mar. 2005 pp. 3737-3747, XP002462388, ISSN: 0022-538X.
Scheffner M et al. “The HPV-16 E6 and E6-AP Complex Functions as a ubiquitin-protein ligase in the ubiquitination of P53” Cell, vol. 75, No. 3, Nov. 5, 1993, pp. 495-505, XP002014083 ISSN: 0092-8674.
Jiang, M., et al., “A bi-functional siRNA construct induces RNA interference and also primes PCR amplification for its own quantification,” Nucleic Acids Research, 2005, vol. 33, No. 18, e151, 7 pages.
Hitchins, M., et al., “Investigation of UBE3A and MECP2 in Angelman Syndrome (AS) and Patients With Features of AS,” American Journal of Medical Genetics, 2004, vol. 125A, pp. 167-172.
First Office Action for Chinese Patent Application No. 200780010541.0, Aug. 6, 2010, 20 Pages.
Examiner's First Report for Australia Patent Application No. 2007230995, Sep. 15, 2010, 2 Pages.
Second Office Action for Chinese Patent Application No. 200780010541.0, Jan. 11, 2011, 6 Pages.
Notification of Office Action for Russian Patent Application No. 2008141977, Nov. 19, 2010, 6 Pages.
Benson John
Bramlage Birgit
Fitzgerald Kevin
Tan Pamela
Vornlocher Hans-Peter
Alnylam Pharmaceuticals, Inc.
Chong Kimberly
Fenwick & West LLP
LandOfFree
dsRNA compositions and methods for treating HPV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with dsRNA compositions and methods for treating HPV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and dsRNA compositions and methods for treating HPV infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2742060